Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Accumulated Expenses: 2021-2022

  • ProQR Therapeutics N.V's Accumulated Expenses fell 28.00% to $8.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was $8.9 million, marking a year-over-year decrease of 28.00%. This contributed to the annual value of $8.9 million for FY2022, which is 30.40% down from last year.
  • According to the latest figures from Q4 2022, ProQR Therapeutics N.V's Accumulated Expenses is $8.9 million, which was down 28.00% from $12.3 million recorded in Q4 2021.
  • ProQR Therapeutics N.V's Accumulated Expenses' 5-year high stood at $12.3 million during Q4 2021, with a 5-year trough of $8.9 million in Q4 2022.
  • Over the past 2 years, ProQR Therapeutics N.V's median Accumulated Expenses value was $10.6 million (recorded in 2021), while the average stood at $10.6 million.
  • Data for ProQR Therapeutics N.V's Accumulated Expenses shows a maximum YoY fell of 28.00% (in 2022) over the last 5 years.
  • Over the past 2 years, ProQR Therapeutics N.V's Accumulated Expenses (Quarterly) stood at $12.3 million in 2021, then fell by 28.00% to $8.9 million in 2022.